or browse our products catalogue
MAPREC assay of poliovirus type 1 (Sabin).100% 480-A, 525-C DNA(1st International Reference Preparation)
Low Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation)
MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard)
High Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation)
Anti-A/Singapore/1/57(H2N2) HA Serum (Sheep 398)
Influenza anti B/Yamanashi/166/98 Serum
Diphtheria Antitoxin Human IgG
Botulinum Type A-E Antitoxin, Human Serum
Influenza anti- A/Chick/Scotland/59 (H5N1) Serum
Influenza Antigen B/Johannesburg/5/99
A/Singapore/1/57 (H2N2) Influenza Virus Antigen
Influenza Antigen A/Duck/Singapore-Q/F119-3/97 (H5N3)
Influenza anti-B/Johannesburg/5/99/ Serum
Interferon Beta (Human, rDNA, Glycosylated) (3rd International standard)
Interferon Beta SER17 Mutein (Human, rDNA derived)
Interferon Beta (Human, Fibroblast-derived, Glycosylated)
Human Anti-Pneumococcal capsule Reference Serum (1st International Standard)
Anti-Meningococcal Immunotype L3,7,9 Monoclonal Antibody
Interleukin-17 (Human rDNA derived)(WHO Reference Reagent)
Influenza anti B/Guangdong/120/2000 Serum
Influenza anti A/Panama/2007/99 (H3N2) HA serum
Botulinum type F antitoxin, equine
Botulinum type C antitoxin, equine
Botulinum Antitoxin Equine Type D
Botulinum type G antitoxin, equine
Anti-Meningococcal Serosubtype P1.7 Monoclonal Antibody
Anti-Meningococcal Serosubtype P1.16 mAb
Influenza Antigen B/Guangdong/120/2000
Anti-Toxoplasma IgG, Human(International Standard)
Anti-Parvovirus B19, plasma, human(2nd International Standard)
Influenza Virus infectious B/Hawaii/10/01
Influenza Antigen A/New Caledonia/20/99
Influenza anti A/Panama/2007/99 Serum
Anti-Meningococcal Serosubtype P1.15 mAb
Anti-Meningococcal Serosubtype P1.4 mAb
Anti-Meningococcal Serosubtype P1.2 mAb
Anti-Meningococcal Serotype P2.2a mAb
Anti-Japanese Encephalitis Virus Plasma, Human
Anti-Japanese Encephalitis (Anti-JE) Virus Negative Control Plasma, Human
HIV (antibody), 1st International Reference Panel
IVIG negative control for use with IVIG + anti-D(WHO Reference Reagent)
IVIG + anti-D for use with negative control IVIG(WHO Reference Reagent)
Biotinylated Brad-5 (Bio-Brad-5)
Tetanus Toxoid (Non-Adsorbed)
Influenza Antiserum A/chick/Italy/1347/99 (H7N1)
Anti-Meningococcal Serotype P3.4 mAb
Anti-Meningococcal Serotype P3.15 mAb
Botulinum Antitoxin Equine Type E
Anti-Meningococcal Serosubtype P1.3 mAb
Protein C Plasma, Human(2nd International Standard)
HTLV-1 (antibody) Monitor Sample
Influenza anti B/Shangdong/9/97 Serum
Anti-Meningococcal Serosubtype P1.1 mAb
Thrombopoietin ( Human rDNA derived)
Anti-Meningococcal Serosubtype P1.14 mAb
Keratinocyte growth factor (KGF, FGF-7)(24-163)(1st WHO Reference Reagent)
Keratinocyte Growth Factor (KGF,FGF-7)(1st WHO Reference Reagent)
Anti-HPA-1a (International Standard)
Anti-B minimum potency reference preparation(International Standard)
Vitamin B12, Serum Folate and holoTC (International standard)
Anti-Meningococcal Serotype P3.21 mAb
Anti-A minimum potency reference preparation(International Standard)
Anti-HPA-3a(minimum potency)(WHO Reference Reagent)
Thyroid-Stimulating Hormone, Recombinant, Human, for Bioassay (1st International standard)
Interleukin - 18 (Human rDNA derived)(WHO Reference Reagent)
Anti-Meningiococcal Serosubtype P1.6 mAb
Influenza anti A/Wyoming/03/03 Serum
Influenza Antigen A/Wyoming/03/03
Anti-Meningococcal Serosubtype P1.10 mAb
Anti-Meningococcal Serosubtype P1.5 mAb
Anti-Meningococcal Serosubtype P1.13 mAb
Influenza anti A/Puerto Rico/8/34 (H1N1) HA Serum
Influenza Antiserum A/chick/Germany/N/49
Influenza Antigen A/New Caledonia/20/99 (IVR-116)
Hepatitis B Surface Antigen subtype adw2, genotype A (International Reference Panel)
Anti-Meningococcal Serosubtype P1.12 mAb
Influenza Virus infectious NYMC X-147
TNF-related Apoptosis-Inducing Ligand (trail), Human, rDNA-derived(1st WHO Reference Reagent)
Influenza Virus infectious A/Wellington/1/2004
Influenza Virus infectious IVR-139
Plasmodium falciparum DNA for NAT Assays(1st International Standard)
Anti-Meningococcal Serotype P3.1 mAb
Influenza Antigen B/ Jiangsu/10/2003
Factor V Leiden, Human gDNA, 1st International Genetic Reference Panel 2004
Influenza anti B/ Neuraminidase Serum
Influenza anti B/Jiangsu/10/2003 HA Serum
Anti-Meningococcal Serogroup W-135 mAb
Anti-Meningococcal Serosubtype P1.19 mAb
Protein C Concentrate, Human(1st International Standard)
Influenza anti A/New Caledonia/20/99 HA Serum
Influenza anti A/New York/55/2004 HA Serum
Influenza Antigen A/New York/55/2004 (H3N2) (NYMC X-157)
Anti-HPA-1a minimum potency reagent (2nd WHO Reference reagent)
Low Molecular Weight Heparin for Molecular Weight Calibration (2nd International Standard).
Prothrombin Mutation G20210A, Human gDNA(1st International Genetic Reference Panel 2005)
Anti-human papillomavirus type 16 serum (1st International Standard)
Alpha-1-Antitrypsin, plasma derived(1st International standard)
Anti Meningococcal Serosubtype P1.9 Monoclonal Antibody
Anti Meningococcal Serotype P2.2b Monoclonal Antibody
Influenza Antigen A/Hiroshima/52/2005 (H3N2) (IVR-142)
Influenza anti A/Wisconsin/67/2005 Serum
Influenza anti B Neuraminidase Serum
Influenza Virus infectious IVR-116
Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 2 (1st International Standard)
Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 3 (1st International Standard)
Pertussis Antiserum(human)1st IS-WHO international Standard.
Pertussis Antiserum (Human) 1st WHO Reference Reagent
Influenza Virus infectious 1 VR-142
Antithrombin Concentrate, Human (3rd International Standard)
Influenza anti A/turkey/Turkey/1/05 (NIBRG-23) HA serum(sheepSH465 & SH466)
Human Papillomavirus (HPV) Type 16 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 18 DNA (1st International Standard)
Influenza Virus Infectious NYMC X-161B (A/Wisconsin/67/2005 HGR)
SARS CoV-1 spike S1 protein
Influenza Antigen A/Solomon Islands/3/2006 (H1N1)(IVR-145)
Influenza anti A/Solomon Islands/3/2006 (H1N1) (IVR-145) HA Serum
Influenza Antigen A/turkey/Turkey/1/2005 (H5N1) NIBRG-23
Influenza Virus infectious IVR-145,
Influenza anti A/HongKong/1073/99 like (H9) HA Serum (sheep)
Influenza anti A/Vietnam/1194/04 (H5N1) HA Serum
Human Plasma Anti-Influenza H5N1 (1st International Standard)
Influenza anti B/Malaysia/2506/2004-HA Serum
Recombinant soluble transferrin receptor (rsTfR)(1st WHO Reference Reagent)
Diphtheria Toxoid (Adsorbed) (4th International Standard)
RhD/SRY Plasma DNA sensitivity standard (1st WHO Reference Reagent)
Blood Coagulation Factor VIIa, Concentrate, Human, 2nd International Standard”
BCG Vaccine of Danish 1331 sub-strain (1st WHO Reference Reagent)
BCG Vaccine of Tokyo 172 sub-strain(1st WHO Reference Reagent)
BCG Vaccine of Russian BCG-I sub-strain(1st WHO Reference Reagent)
Influenza anti A/mallard/Netherlands/12/2000 (H7) HA serum (NIBRG-60) (sheep SH474 AND SH475)
Monitor sample for HBsAg 0.05IU/ml
Hepatitis B Surface Antigen (HBsAg) British Working Standard 0.2 IU/ml
Influenza Antigen A/Anhui/1/05 (H5N1) IBCDC-RG-6
Anti-A and anti-B in IVIG: Positive control for haemagglutination tests (WHO Reference Reagent)
Blood Coagulation Factor VIII and Von Willebrand Factor in Plasma (6th I.S.)
Meningococcal Group C Polysaccharide
Unfractionated Heparin (6th I.S.)
Influenza Antigen A/mallard/Netherlands/12/00(H7N3) NIBRG-60
Influenza antiserum A/Anhui/1/05 (H5)
Influenza Virus infectious NYMC X-171B
Influenza Virus infectious NIB-50
Influenza Virus infectious IVR-149
Influenza Antigen A/Brisbane/59/2007 (IVR-148) (H1N1)
Influenza Virus Infectious NIBRG-91 (H9N2)
Influenza Anti N1 Neuraminidase Serum SH485
Influenza Antigen B/Florida/4/2006
Influenza Virus Infectious NIBRG-12 (H5N1)
Influenza Virus Infectious NIBRG-23 30060 VE3 (H5N1)
Fragile X Syndrome gDNA (1st International Genetic Reference Panel)
Haemophilia A, Intron-22 inversion, gDNA, (1st International Genetic Reference Panel)
Influenza Antigen B/Malaysia/2506/2004
Influenza anti A/chick/Hong Kong/G9/1997/(H9) HA serum (NIBRG-94)(H9N1)
Thyroid Stimulating Antibody (2nd I.S.)
Influenza Antigen A/HongKong/1073/99 (H9N2)
Influenza anti A/Cambodia/R0405050/2007 (H5) HA serum (NIBRG-86)
Influenza Antigen A/Cambodia/RO405050/2007 (H5N1)
Tetanus Toxoid Adsorbed (4th International Standard)
Influenza Antigen A/chick/Hong Kong/G9/1997 (H9N2) NIBRG-91
Streptodornase (2nd International Standard)
Influenza anti A/Brisbane/10/2007- like HA serum
Influenza Virus Infectious NIBRG-107 VE2 30480
Influenza Virus Infectious NIBRG-63 VE2 30500 (H7N1)
Influenza Virus Infectious NIBRG-109 VE2 30490
C1- Inhibitor, Concentrate (1st International Standard)
Antithrombin, Plasma (3rd International Standard)
C1 Inhibitor (Plasma)(1st International Standard)
Sex Hormone Binding Globulin.(2nd International Standard)
Influenza Antigen A/mallard/England/727/2006 (H2N3)NIBRG-107
Influenza Antigen A/Brisbane/10/2007-like (Prepared from A/Uruguay/716/2007 (NYMC X-175C))
Influenza Virus Infectious B/Brisbane/33/2008 30720 E5
Influenza Virus Infectious IVR-148
Influenza virus infectious NYMC X-175C
Influenza antiserum A/Japan/305/57 (H2)
Influenza Antigen A/New York/107/2003 (H7N2)NIBRG-109
Influenza anti A/mallard/England/727/2006 (N3) NA serum (NIBRG-107) (Sheep SH503)
Parvovirus B19 DNA Nucleic Acid Amplification Technology(NAT) based assays Genotype Panel(1st International Standard)
Influenza Virus Infectious NIBRG-122
Granulocyte Colony Stimulating Factor (Human, rDNA Derived)(2nd International Standard)
Genetic Reference Panel, for the quantitation of BCR-ABL translocation by RQ-PCR (1st I.S.)
Prader Willi & Angelman Syndromes, Human gDNA,(1st International Genetic Reference Panel)
Influenza anti A/New York/107/2003 (H7) HA serum (Sheep SH504 and SH505)
Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification Techniques (1st International Standard)
Anti-Meningococcal factor H binding protein variant 1 (JAR4) monoclonal antibody
Blood coagulation Factors II, VII, IX, X Plasma (4th International Standard 2010)
Influenza Antigen A/California/7/09 (H1N1)v (NYMCX-179A)(Cell Derived)
Influenza Antigen A/Vietnam/1194/2004 (H5N1) NIBRG-14
Chagas (anti-Trypanosoma cruzi II) antibody in human plasma(1st International Standard)
Chagas (anti-Trypanosoma cruzi I) antibody in Human Plasma (1st International Standard)
Influenza Antigen A/California/7/09 (H1N1)v (NIBRG-121xp) (Egg Derived)
Human anti-Haemophilus influenzae b reference serum
Transforming Growth Factor-BETA 3 (Human, rDNA derived TGF-ß 3) (1st International Standard)
Influenza Virus Infectious IVR-153
Fibrinogen Concentrate (B)(2nd International Standard)
Epstein-Barr Virus for Nucleic Acid Amplification Techniques(1st International Standard)
Fibrinogen Plasma (D)(3rd International Standard)
GLIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF), human, rDNA-derived
Influenza Virus Infectious NIBRG-121xp
Placental growth factor Ala 21 - Arg 149, human, rDNA-derived (PlGF, PlGF-1)
Influenza Virus Infectious NYMC X-185
Influenza Virus Infectious NIB-64
Anti-Human Neutrophil Antibody 1a WHO Reference Reagent
Pro-Insulin, human (1st International Standard)
Influenza Virus Infectious IVR-155
Influenza Serology Antigen Reagent X-179A (H1N1pdm) for HI Assay
Influenza Antigen A/Wisconsin/15/09 (H3N2) (NYMCX-183)
Reteplase Reference Material
Influenza Anti A/Brisbane/59/2007 (IVR 148)(H1N1) HA serum
Diphtheria Polyclonal Antibody
Diphtheria Monoclonal Antibody
Tetanus Polyclonal Antibody
Tetanus Monoclonal Antibody
Anti-human papillomavirus[HPV] 18 serum (1st International Standard)
Anti-human leukocyte antigen antibodies (negative plasma)
Oral Poliovaccine Sabin Type 1 reference strain [LS-c, 2ab strain].
Oral Poliovaccine Sabin Type 3 reference
Interleukin-29 (Interferon Lambda, Human, rDNA derived) WHO Reference Reagent
Endotoxin (3rd International Standard)
Anti-malaria (Plasmodium falciparum) human serum(1st WHO Reference Reagent)
Influenza antibody (Human) to A/California/7/2009 'like' (H1N1v) virus (2nd International Standard)
Influenza Anti N2 Neuraminidase Serum SH395 & SH396
Influenza Anti A/California/7/2009 (N1) NA Serum
Influenza Virus Infectious IVR-158
Blood Group Genotyping Reference Reagent RBC1 (OR1R2)(WHO Reference Reagent)
Blood Group Genotyping Reference Reagent RBC12 (ODpsi)(WHO Reference Reagent)
Blood Group Genotyping Reference Reagent RBC4 (AR1R1)(WHO Reference Reagent)
Blood Group Genotyping Reference Reagent RBC5 (Brr)(WHO Reference Reagent)
Toxoplasma gondii DNA Nucleic Acid Amplification Techniques(1st International Standard)
Factor VII Concentrate (2nd International Standard)
Influenza Antigen A/California/7/2009-like(NIB-74)
Diphtheria Antitoxin Human IgG(1st International Standard)
BCG vaccine of Moreau-RJ sub-strain (1st WHO Reference Reagent)
pCAGGS-SARS-CoV-2-Spike
VeroE6/TMPRSS2
pCAGGS_SARS-CoV-2_Spike D614G
pCAGGS-SARS-CoV-2-Spike Bristol Deletion
Inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020
Nucleic acid extracts from inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020
pCRII-SARS-CoV-2 (5'UTR-NSP2)
pCRII-SARS-CoV-2 (NSP4-NSP8)
pCRII-SARS-CoV-2 (NSP15-NSP16)
pCRII-SARS-CoV-2 (ORF3a-ORF6)
VeroE6-ACE2
VeroE6-ACE2-TMPRSS2
A549-ACE2-TMPRSS2
A549-ACE2 Clone8
A549-ACE-2 Clone 8-TMPRSS2
SARS-CoV-2 Trimeric Spike 50ug (1mg/ml in PBS) Sterile #28.05.2020
HEK293T-ACE2-TMPRSS2
Anti-SARS-CoV-2 Nucleocaspid protein (CR3009)
Anti-SARS-CoV-2 Nucleocapsid protein (CR3018)
pl.18SARS-CoV-2-Spike (B.1.1.7) 1ug (100ng/ul) lot #24032021
pl. 18SARS-CoV-2-Spike (B.1.351) 1ug (100ng/ul) lot #24032021
4% formaldehyde inactivated SARS CoV-2 BetaCoV/Australia/VIC01/2020 from VeroE6/TMPRSS2
Acid/heat inactivated SARS-CoV-2 (B.1.1.7) lot 17022021
SARS-CoV-2 Alpha (B.1.1.7) Purified RNA extracts lot 20052021
Acid/Heat Inactivated SARS-CoV-2 Beta (B.1.351 lineage)
Acid/Heat Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage
Inactivated (acetic acid + heat) SARS-CoV-2 Gamma (P.1 lineage)
0.01% Formaldehyde Inactivated SARS-CoV-2 Beta (B.1.351 lineage)
0.01% Formaldehyde Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage)
SARS-CoV-2 Nucleocapsid protein (His tagged)
SARS-CoV-2 Nucleocapsid protein 203/204:RG>KR (His tagged)
Inactivated (Acetic Acid + Heat)SARS-CoV-2 Omicron (BA.1 sublineage)
SARS-CoV-2 XE Recombinant isolate
SARS-CoV-2 XF Recombinant isolate
SARS-CoV-2 BA.12.1 isolate
SARS-CoV-2 BA.4 isolate
SARS-CoV-2 BA.2 isolate
HEK293T-ACE2-30F-PLP2
SARS-CoV-2 Omicron - BA.1 lineage
SARS-CoV-2 Omicron - BA.2.75.3 lineage
SARS-CoV-2 Omicron - BA.4.6 lineage
SARS-CoV-2 Omicron - BA.2.3.20 lineage
SARS-CoV-2 Omicron - BA.5.1.17 lineage
SARS-CoV-2 Omicron - BF.7.5 lineage
SARS-CoV-2 Omicron - BF.1 lineage
SARS-CoV-2 Omicron - BE.1 lineage
SARS-CoV-2 Omicron - Recombinant XAH lineage
SARS-CoV-2 Omicron - Recombanant XAZ lineage
SARS-CoV-2 Omicron - BA.4 lineage
SARS-CoV-2 Omicron - BA.5.1 lineage
SARS-CoV-2 Omicron - Recombinant XAK lineage
Nucleic acid extracts from inactivated (acetic acid + heat) SARS-CoV-2 Gamma (P.1 lineage)
Nucleic acid extracts from inactivated (acetic acid + heat) SARS-CoV-2 Beta (B.1.351 lineage)
Nucleic acid extracts from inactivated (acetic acid + heat) SARS-CoV-2 Delta (B.1.617.2 lineage)
SARS-CoV-2 XBB.1.1 isolate
SARS-CoV-2 XBB.2 isolate
SARS-CoV-2 XBB.1.5 isolate
SARS-CoV-2 CH.1.1 isolate
SARS-CoV-2 Gamma - P.1 lineage
SARS-CoV-2 Alpha - B.1.1.7 lineage
SARS-CoV-2 Beta - B.1.351 lineage
SARS-CoV-2 Epsilon - B.1.427 lineage
SARS-CoV-2 Epsilon - B.1.429 lineage
SARS-CoV-2 Eta - B.1.525 lineage
SARS-CoV-2 Iota - B.1.526 lineage
SARS-CoV-2 Delta - B.1.617.2 lineage
SARS-CoV-2 Mu - B.1.621 lineage
SARS-CoV-2 Omicron - BA.1.1 lineage
SARS-CoV-2 Omicron - BA.2 lineage
SARS-CoV-2 Omicron - BA.2.9.3 lineage
SARS-CoV-2 Omicron - Recombinant XZ lineage
SARS-CoV-2 Omicron - Recombinant XBB lineage
SARS-CoV-2 Deltacron - Recombinant XD lineage
SARS-CoV-2 Omicron - Recombinant XN lineage
SARS-CoV-2 Omicron - BQ.1 lineage
SARS-CoV-2 Omicron - BQ.1.14 lineage
Anti-SARS-CoV-2 RBD Wuhan-variant specific monoclonal antibody, Clone 486
Anti-SARS-CoV-2 RBD Delta-variant specific monoclonal antibody, clone 215
Anti-SARS-CoV-2 RBD Delta-variant specific monoclonal antibody, Clone 215
Anti-SARS-CoV-2 RBD Omicron-variant specific monoclonal antibody, clone 304
Anti-SARS-CoV-2 RBD Cross reactive monoclonal antibody, clone 175
SARS-CoV-2 XBB.1.16 isolate
SARS-CoV-2 XBB.2.3 isolate
SARS-CoV-2 EG.5.1.1 isolate
SARS-CoV-2 BA.2.86 isolate
IPV ELISA MAbs Type 1, 2 and 3 (Type 2; No: 1050)
Influenza Virus infectious NYMC X-187
Factors II and X Concentrate (4th International standard)
Influenza Antigen A/California/7/2009 (H1N1) Like (A/Brisbane/10/2010- cell derived)
Erythropoietin, recombinant, for Bioassay (3rd International Standard)
(3rd International Standard) Low Molecular Weight Heparin
High Molecular Weight Urokinase(2nd International Standard)
Influenza anti-A/Perth/16/2009 HA Serum
Anti-human CD4 FITC conjugated 0.5ml
Biosynthetic Human Insulin (2nd WHO international Standard)
Blood Group Genotyping Reference Reagents Panel (WHO Reference Reagent)
Chagas Antibody Reference Panel ( 1st International Standard)
Influenza Virus Infectious NIB-79
Immunoglobulin E (IgE) human serum (3rd International Standard)
Viral Multiplex Reference
Influenza Virus Infectious NYMC X-217
International Standard for IPV 12/104 (3rd International Standard)
Influenza Antigen B/Hubei-Wujiagang/158/2009 (NYMCBX-39)
Influenza Antigen B/Wisconsin/1/2010 (cell derived)
Influenza Antigen A/Victoria/210/2009 (H3N2) (NYMCX-187)
Influenza Antigen A/Victoria/361/2011 (H3N2) (IVR-165)
Influenza anti-A/Victoria/361/2011-like HA serum
Influenza anti-B/Wisconsin/1/2010-like HA serum
Influenza virus infectious A/turkey/Italy/3889/1999 (H7N1)
Tumour Necrosis Factor alpha (human rDNA derived)(3rd International Standard)
Pegylated Granulocyte Colony Stimulating Factor (Human, rDNA derived) (1st International Standard)
Influenza virus infectious NYMC BX-39
Influenza Virus infectious IVR-165
Parvovirus B19 (3rd International Standard)
HIV-1 NAT subtypes (Main)(2nd International Reference Panel Preparation)
HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)(3rd International Standard)
Vi polysaccharide of C freundii WHO 1st International Standard
Influenza anti A/Mallard/England 727/2006 (H2) HA Serum
ADAMTS 13 Plasma (1st International Standard)
Diphtheria Toxin 1Lf/ml
Anti-meningococcal serogroup Y monoclonal antibody
Negative Control IVIG (for use with IVIG and Anti-D)
Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP)(2nd International Standard)
Activated Blood Coagulation Factor XI (FXIa), Human (1st International Standard)
Influenza Antigen B/Massachusetts/02/2012
Anti-Meningococcal serogroup B monoclonal antibody
Influenza Antigen A/Texas/50/2012 (NYMC X-223)
Influenza Antigen A/Texas/50/2012 (NYMC X-223A)
Erythropoietin Antibody Reference Panel Negative Control Antibody (1st WHO Reference Panel)
Influenza anti-B/Brisbane/60/2008-like HA serum
Influenza Virus Infectious NIBRG-269
Antibodies, Human, to Toxoplasma gondii (4th International Standard).
Influenza Antigen B/Massachusetts/02/2012 (Egg derived)
C-Peptide, Human (1st International Standard).
IVIG + anti-D for use with negative control IVIG
Influenza Antigen B/Massachusetts/02/2012 (Cell Derived)
Influenza Antigen A/Texas/50/2012 (NYMC X-223A) (Cell derived)
Influenza Antigen A/California/7/2009 (H1N1pdm)(NYMC X-179A)
Influenza anti-A/Anhui/1/2013 (N9) NA Serum
Human Measles Mvi/Moscow Rus/1988 Genotype A Virus for Nucleic Acid Amplification Techniques
Lupus Anticoagulant (1st International Reference Panel)
Influenza Virus Infectious NIBRG-88
Influenza Anti-A/Texas/50/2012-like HA Serum
Influenza Anti-B/Massachusetts/02/2012-like HA Serum
Influenza Virus Infectious NIB-74
Influenza Virus Infectious NIB-74xp
TNF Rec II- FC Fusion protein (1st International Standard)
Plasmin (4th International Standard)
Diphtheria Toxoid for use in Flocculation Test (3rd International Standard)
HIV-1 Circulating Recombinant Forms RNA (1st International Reference Panel)
Anti-meningococcal factor H binding protein variant 1 (JAR5) monoclonal
Polio Anti Sabin type 1 (inactivated) Serum
Polio Anti Sabin type 2 (inactivated) serum
Polio Anti Sabin type 3 (inactivated) serum
Influenza virus Infectious NIB-85. 36210 E5
Influenza Virus Infectious. A/Almaty/2958/2013. 35790 E4
Influenza antigen B/Brisbane/60/08
Anti-EV71 serum LOW (WHO Reference Reagent)
Tetanus Immunoglobulin, Human (2nd WHO International Standard)
FEIBA Concentrate 2nd NIBSC Working Reference Standard
Meningococcal serogroup A polysaccharide (1st WHO International Standard).
Influenza virus infectious NIBRG-267 (H7N9)
Influenza Virus Infectious NIBRG-268 (H7N9)
Influenza virus infectious NYMC X-223A
Influenza virus infectious. NYMC x-233
Influenza virus infectious NYMC X-233A
Meningococcal serogroup A polysaccharide
Influenza Virus Infectious NYMC X-223
Human Papillomavirus (HPV) 11 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 45 DNA (1st International Standard)
JC Virus (JCV) DNA (1st International Standard)
Influenza virus infectious NYMC X-179A
1st International Standard for Anti EV71 Serum Human
Influenza anti-N2 Neuraminidase serum (A/Victoria/361/2011)
Influenza Antigen B/Brisbane/60/2008 (NYMCBX-35)(Cell Derived)
Human Blood Factor IX Concentrate (5th International Standard).
Meningococcal group X polysaccharide (1st WHO International Standard)
High titre anti-A in IVIG working reference reagent
Botulinum Type A Antitoxin, Equine
HBV,HCV,HIV Multiplex
Influenza Antigen A/Puerto Rico/8/34 (HINI)
Influenza virus infectious NYMC X-247
Biological activities of Rituximab WHO 1st International Standard
BK Virus (BKV)(1st International Standard)
Influenza virus infectious. A/Switzerland/9715293/2013
Influenza Virus Infectious A/South Australia/55/2014
Influenza Virus Infectious A/Stockholm/6/2014
Influenza Virus Infectious. A/Norway/466/2014
Influenza Virus Infectious IVR-175
Recombinant Tissue factor
Influenza Antigen A/Switzerland/9715293/2013 (NIB88)
Human Papillomavirus (HPV) Type 6 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 31 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 33 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 52 DNA (1st International Standard)
Human Papillomavirus (HPV) Type 58 DNA (1st International Standard)
Influenza Antigen B/Brisbane/9/2014 (Egg Derived)
High titre anti-A and anti-B in serum (WHO Reference Reagent).
Influenza Virus Infectious NYMC X-243 40180 E13
Influenza Virus Infectious IVR-178 40200 E7
Influenza Virus Infectious NIB-88
Factor IX activated (FIXa) 2nd WHO International Standard
Influenza Anti NIBRG-301 (H5) HA Serum (Sheep SH624 and SH625)
Influenza Virus Infectious NIB-91
Influenza Antigen B/Utah/9/2014 (Cell Derived)
Activated Blood Coagulation Factor X (FXa), Human
Influenza Antigen A/South Australia/55/2014 Cell derived
Ancrod
Bordetella pertussis toxin (20µg). (2nd International Standard)
Clinical Virology Multiplex I: Immunodeficiency panel working reagent for Nucleic Acid Amplification Tests (NAT)
Influenza Anti-A Switzerland/9715293/2013-Like HA serum
EBOV RNA NP-VP35-GP in-run control
EBOV RNA VP40-L in-run control
Batroxobin
Influenza Virus Infectious NIB-92
Influenza Virus Infectious NIB-93
Influenza Virus Infectious NYMC X-263
Influenza Virus Infectious NIBRG-306
Lupus (oligo-specific) anti-dsDNA antibodies WHO Reference Reagent
Blood Coagulation Factor XI, 2016 Plasma Human (2nd International Standard). Blood Coagulation Factor XII, 2017 Plasma, Human (1st International Standard)
7th British Working Standard for Blood Coagulation Factors II, IX, X Concentrate
Influenza Virus Infectious NYMC X-263B
Influenza Virus Infectious NYMC X-263A
Influenza Virus Infectious NYMC X-257A
Influenza Virus Infectious NYMC X-261
Influenza Virus Infectious NYMC BX-53C
Anti-EBOV plasma, human (WHO Reference Reagent)
EBOV RNA NP-VP35-GP (WHO Reference Reagent)
EBOV RNA VP40-L (WHO Reference Reagent)
Influenza Virus Infectious B/Texas/2/2013 41340 E7
Influenza Antigen A/New Caledonia/71/2014 (NYMCX-257A)(Egg derived antigen)
Erythropoietin Antibody Reference Panel A (1st WHO Reference Panel)
Erythropoietin Antibody Reference Panel B (1st WHO Reference Panel)
Influenza Anti A/Anhui/1/2013 (H7) HA Serum (Sheep SH644 & SH645)
Influenza Virus Infectious NYMC BX-31
1st International Standard for Ebola virus (EBOV) antibodies Sierra Leone Convalescent Plasma Pool
HHV-6 Virus 1st WHO International Standard
1st WHO International Reference Reagent CD4 T-cells (human)
ICS Positive Control-Lymphocytes
Hepatitis A Virus VL For Nucleic Acid Amplification Techniques (3rd International Standard)
Sabin monovalent Polio vaccine type 2 (1st International Standard)
Influenza Virus Infectious B/Brisbane/46/2015
Influenza Virus Infectious NYMC BX-35 41950 E11
Parathyroid hormone 1-34, recombinant, human, 2nd WHO International Standard
Influenza antigen A/California/7/09 (H1N1) (NYMC-X181)
Influenza Virus Infectious A/PR/8/34
Zika Virus Working Reagent for Nucleic Acid Amplification Testing (NAT)
Influenza anti - A/California/7/09 HA serum
Influenza Antigen B/Brisbane/60/2008 (NYMC BX-35) (Egg Derived)
WHO 1st International Reference Panel for Genomic JAK2 V617F
Native Vi polysaccharide (S. Typhi) (1st International Standard)
Anti-Typhoid capsular Vi polysaccharide Ig (Human) 1st WHO International Standard
Meningococcal Serogroup W Polysaccharide
Sabin bivalnet Polio vaccines types 1 and 3 (1st International Standard)
WHO International Standard 1st International Standard for Infliximab
Influenza Anti-A/Hong Kong/4801/2014-like HA Serum
Mullerian Inhibiting Substance/Anti-Mullerian Hormone, human, recombinant (WHO reference Reagent)
Influenza Anti - B/Brisbane/60/2008-HA serum
HIV-1 RNA (4th International Standard)
Sabin monovalent Polio vaccine type 1(1st International Standard)
Influenza Virus Infectious NIB-58
OPV reference mOPV 3
7th WHO International Standard for Rabies Vaccine
Meningococcal serogroup Y Polysaccharide
Influenza Virus Infectious NIB-97 42090 E7
HIV-1 P24 Antigen (1st international reference panel)
HIV-2 p26 Antigen (VLP)-HIV-2 A7312 (1st WHO Reference Reagent)
Influenza Antigen A/Anhui/1/2013 (NIBRG-268) (H7N9)
Influenza Virus Infectious NIB-98 42110 E7
1st International Reference Panel for genomic KRAS codons 12 and 13 mutations
Influenza Virus Infectious X-273
Influenza Virus Infectious IVR-180 42400 E3/D7/E1
Influenza Virus Infectious X-275A 42010 E13
Anti-D Immunglobulin control preparation
Influenza Virus Infectious X-285 42430 ExE1
Antiserum to Respiratory Syncytial Virus (WHO 1st International Standard)
Influenza Antigen A/Hong Kong/4801/2014 (NYMC X-263B)
Influenza Virus Infectious X-283A 42420 ExE1
Influenza Virus Infectious X-285A 42440 ExE1
Influenza Antigen A/Singapore/GP1908/2015 (IVR-180)
Human Immunodeficiency Virus type 2 RNA (HIV-2) for Nucleic Acid Amplification Techniques (2nd International Standard)
Tetanus Toxoid for use in Flocculation Test (3rd International Standard)
Zika Antibody Working reagent
Human Adenovirus DNA for nucleic acid amplification techniques (1st WHO international Standard).
Anti-D Immunoglobulin (3rd International Standard)
WHO Anti-EBOV Convalescent Plasma (International Reference Panel)
Anti-Asian Lineage Zika Virus Antibody (human) (1st international standard)
Streptokinase (4th WHO International Standard)
Influenza Virus Infectious NIB-96 41920 E7
Influenza Virus Infectious NYMC X-291 42530 E8
3rd International Standard for Prekallikrein Activator
Influenza Virus Infectious NYMC X-291A 42540 E8
HSV-1
Blood Coagulation Factor V, Plasma, Human. (WHO 2nd International Standard)
Plasmodium falciparum antigens (1st International Standard)
Fimbrae monoclonal antibody, clone 1-7
Prostate Specific Antigen (human)(total: PSA-ACT + free PSA)
Prostate Specific Antigen (human) (Free), (2nd WHO International Standard)
Influenza Anti-A/Michigan/45/2015-like HA Serum
HSV-2
Influenza Anti NIBRG-306 (H5) HA Serum (sheep SH672 and SH637)
Influenza Virus Infectious NIBRG-375 (H7N9)
Influenza Antigen A/Duck Vietnam/NCVD-1584/2012 (NIBRG-301) (H5N1)
Influenza Antigen A/Michigan/45/2015 (NYMC X-275)
Influenza Virus Infectious CNIC-1701 42910 E9
Sabin Inactivated Polio Vaccine (sIPV) (WHO 1st international Standard)
Influenza Virus Infectious NYMC X-299 42920 E10
Influenza Virus Infectious B/Maryland/15/2016 42800 E5
Influenza Virus Infectious NIB-103 42610 E7
Influenza Virus Infectious NYMC X-297 42940 E11
Influenza Virus Infectious NIB-104
WHO 1st International Standard for TAFI, Plasma
1st International Standard for Darbepoetin
14th British Standard for Coagulation Factor VIII Concentrate, Human.
Influenza Virus Infectious IVR-186 43310 E8
WHO Reference Reagent Anti-human leukocyte antigen antibodies (negative serum)
Tumor Necrosis Factor alpha (human rDNA derived)
Adalimumab (1st WHO International Standard)
Anti-human leukocyte antigen antibodies (strong positive plasma)
5% Immunoglobulin (Negative Control)
Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (NIB-104)
Influenza Virus Infectious NYMC BX-69 43220 E13
Influenza Virus Infectious NYMC BX-69A
Influenza Virus Infectious B/Alabama/2/2017
Influenza Virus Infectious A/Michigan/45/2015 43470 E5
Influenza Antigen B/Maryland/15/2016
Influenza Antigen B/Maryland/15/2016 (NYMC BX-69A)
Influenza anti-A/Singapore/INFIMH-16-0019/2016- like HA serum
Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (IVR-186)
Influenza anti-A/Guangdong-17SF003/2016 (H7) (NIBRG-375) HA Serum
WHO International Standard Enterovirus 71 (EV71) Inactivated vaccine (Geno Group C4)
1st International Standard for HCT 15 Cancer Genome
WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group C4)
1st International Standard for MOLT-4 Cancer Genome
WHO Reference Reagent Lentiviral Vector Copy number by digital PCR 6.75 log 10 LV copies/ampoule
WHO Reference Reagent Lentiviral Vector Copy number by quantitative PCR 6.89 log 10 LV copies/ampoule
Influenza Virus Infectious NIBRG-301 (H5N1)
Influenza Virus Infectious NIBRG-14 (H5N1)
Influenza Virus Infectious NYMC X-307A
Influenza Virus Infectious NYMC X-307
WHO 1st Reference Reagent for Lentiviral Vector Integration Site Analysis
Pertussis antiserum (Human) panel
Bordetella pertussis, pertactin, PRN
WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group B4)
Influenza Virus Infectious NYMC X-311
1st International Standard for ATDB102 Genome
Influenza Virus Infectious NIB-112 43990 E6
Influenza Virus Infectious A/Switzerland/8060/2017
Influenza anti-B/Colorado/06/2017-like HA serum
Influenza Virus Infectious A/Brisbane/1/2018
2nd International Standard for Diphtheria Antitoxin Equine
Hepatitis C virus RNA for nucleic acid amplification techniques (6th WHO International Standard)
Influenza Antigen A / Switzerland / 8060 / 2017 (NIB-112)
Influenza Antigen A / Brisbane/ 01/2018 (NYMC X-311)
Influenza Anti-A/Switzerland/8060/2017-like (H3N2) HA Serum
Influenza Virus Infectious NYMC X-275 (Influenza Reagent)
Influenza Antigen A/Guangdong/17SF003/2016. NIBRG-375 (H7N9)
1st International Standard Anti-citrullinated peptide antibodies (ACPA)
West Nile Virus - International Standard
WHO Reference Reagent for West Nile Virus lineage 2 RNA for NAT-based assays
Bevacizumab (1st WHO International Standard)
Anti-HPA 15b minimum potency reagent (WHO Reference Reagent)
Influenza Virus Infectious IVR-190 44250 E12
Influenza Virus Infectious B/Colorado/06/2017 43460 E7
Influenza Virus Infectious NIB116-B 44230 E5
Influenza Antigen A/Brisbane/02/2018 (IVR-190) (H1N1)
Influenza Virus Infectious NYMC X-327 44280 E17
Influenza Virus Infectious A/Kansas/14/2017 43880 E8
Human Chorionic Gonadotropin (hCG) (6th International Standard)
Von Willebrand Factor Concentrate (WHO 3rd International Standard)
Influenza anti-A/Brisbane/02/2018-like (H1N1) HA Serum (Sheep 698, 699, 700, 701)
Influenza antigen A/Kansas/14/2017 (NYMC X-327) (H3N2)
Influenza Virus Infectious IVR-195 44300 E9
Trastuzumab (1st WHO international Standard)
Influenza Virus Infectious NIB-110
Anti-Human Neutrophil Antibody 3a WHO Reference Reagent
1st WHO Plasmodium Vivax Antigen (LDH)
Ferritin (Human, Recombinant)
Influenza Virus Infectious X-327 A 44310 E18
Influenza Virus Infectious CNIC-1903
Influenza Virus Infectious CNIC-1902 44320 E10
Influenza anti-A/Kansas/14/2017 - Like (H3N2) HA Serum
Influenza Antigen A/Kansas/ 12/2017 (IVR-195) (H3N2)
Panel of recombinant antibody controls for Cytokine Release Assays
Influenza Virus Infectious A/California/7/09 44430 E6
VZV Nucleic acid amplification techniques (1st WHO International Standard)
Insulin-like Growth Factor I, for Immunoassay (2nd WHO international Standard)
Influenza Virus Infectious BVR-11
Influenza Virus Infectious IVR-197 (H3N2) 44850 E14
Influenza Virus Infectious B/Victoria/705/2018
1st WHO International Standard for Anti-MERS-CoV Immunoglobulin G (Human)
Non WHO Reference material Working reagent for Anti-MERS-CoV Antibody
3rd International Standard Thrombin
Influenza Virus Infectious IVR-202 (H3N2) 44880 E10
Influenza Virus Infectious B/Brisbane/35/2018
1st WHO Reference Reagent for anti-malaria (Plasmodium Vivax) human plasma
Influenza Antigen A/Newcastle/82/2018 (H3N2) (cell derived)
Influenza Virus Infectious X-181 45030 E8
Influenza Antigen B/Victoria/705/2018 (BVR-11) (B Victoria Lineage)
Influenza Antigen B/Darwin/7/2019 (B Victoria Lineage) (Cell Derived)
Influenza Antigen A/South Australia/34/2019 (IVR-197) (H3N2)
Influenza Anti-A/South Australia/34/2019-Like (H3N2) HA Serum (Sheep 712, 713, 714, 715, 716)
Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV16, HPV18, HPV6, HPV11
Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV31, HPV33, HPV45, HPV52, HPV58
Influenza Virus Infectious A/South Australia/34/2019
Influenza Virus Infectious A/Christchurch/516/2019 H3N2 45010 E4
Influenza Antigen B/Washington/02/2019 (B Victoria Lineage)
British Working Standard for Anti-HCV
Third WHO International Standard for Anti-Rabies Immunoglobulin
1st International Standard for human vascular endothelial growth factor-165 (VEGF165)
Working Standard for Anti-Rabies Immunoglobulin
Influenza Virus Infectious BX-85C 45230 E13
Influenza Virus Infectious CNIC-1906 44910 E3+3/E9/E1
Anti-thyroid peroxidase antibodies (1st WHO International Standard)
Influenza Virus Infectious NIB-121 (H3N2) 45180 E7/E1/E5
First WHO International Standard for anti-human papillomavirus type 33 serum
First WHO International Standard for anti-human papillomavirus type 52 serum
First WHO International Standard for anti-human papillomavirus type 6 serum
First WHO International Standard for anti-human papillomavirus type 58 serum
Influenza Antigen A/Victoria/2454/2019 (IVR-207) (H1N1)
Influenza Antigen B/Singapore/INFTT-16-0610/2016 (B Yamagata lineage) (cell derived)
Influenza Antigen A/Guangdong-Maonan/SWL1536/2019 (CNIC-1909) (H1N1)
Influenza Anti-A/ Guangdong-Maonan/SWL 1536/2019-like (H1N1) HA Serum (Sheep 723, 724, 725, 726, 727, 728)
Influenza anti-A/hongKong/2671/2019-like (H3N2) HA Serum (Sheep 729, 730, 731, 732, 733, 734)
Influenza anti-B/Washington/02/2019-like (B Victoria lineage) HA Serum (Sheep 737, 738, 739, 740, 741, 742)
Influenza anti-N2 Neuraminidase Serum (A/South Australia/34/2019) (Sheep 735, 736)
Influenza Virus Infectious IVR-207 (H1N1) 45370 E4/E6/E1
Influenza Virus Infectious A/Victoria/2454/2019 (H1N1) 45360 E4/E1
Influenza Antigen A/HongKong/2671/2019 (NIB-121)(H3N2)
IVIG + Anti-D (13/148) x2 Negative Control IVIG (12/300) x2
Influenza Antigen A/HongKong/2671/2019 (IVR-208) (H3N2)
Working Reagent for SARS-CoV-2 RNA
First WHO International Standard for Mycobacterium tuberculosis (H37Rv) DNA for NAT-based assays
NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (20/162)
Influenza Virus Infectious BX-87C (B/VIC) 45460 E3/E10/E1
NHS winter Multiplex Working Reagent for Nucleic acid amplification testing (NAT)
1st International Standard for anti-EV68 Serum
First WHO International Standard for anti-human papillomavirus type 11 serum
First WHO International Standard for anti-human papillomavirus type 31 serum
First WHO International Standard for anti-human papillomavirus type 45 serum
Influenza A (H1N1) Panel
Influenza A (H3N2) Panel
Influenza B Panel
RSV A Panel
RSV B Panel
SARS-CoV-2 Panel
Anti-Lassa Virus Antibodies (1st International Standard)
Influenza Virus Infectious IVR-216 (H1N1) 45630 E4/D6/E1
Follicle Stimulating Hormone (3rd International Standard)
Influenza Virus Infectious IVR-217 (H1N1) 45640 E4/D6/E1
Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum (Sheep 749, 750, 751, 752, 753, 754)
Influenza Virus Infectious X-349 (H1N1) E3/E9/E1 45720
Influenza Virus Infectious X-349A (H1N1) E3/E11/E1 45730
WHO Reference Reagent Human Monoclonal Antibody for Poliovirus Type 1
WHO Reference Reagent Human Monoclonal Antibody for Poliovirus Type 2
WHO Reference Reagent Human Monoclonal Antibody for Poliovirus Type 3
WHO Reference Reagent Human Monoclonal Antibody for Poliovirus Types 1, 2 and 3
Influenza Virus Infectious X-341 + 1P (H3N2)
2nd International Standard for Factor XIII Plasma, Human
Influenza Virus Infectious X-347 (H3N2)
Influenza Virus Infectious X-347A (H3N2)
WHO International Reference Reagent for GUT Microbiome analysis by NGS (Gut-Mix RR)
WHO Reference Reagent for GUT Microbiome analysis by NGS (DNA-Gut-HiLo)
Influenza Virus Infectious A/Cambodia/E0826360/2020 (H3N2)
2nd WHO International Standard For Meningococcal Capsular Group C Polysaccharide
Influenza Virus Infectious IVR-221 (H3N2)
Influenza Virus Infectious A/Singapore/INFIMH-16-0019/2016 (H3N2)
Influenza Antigen A/Cambodia/e0826360/2020 (IVR-224) (H3N2)
Working Reagent for Lassa virus RNA
First WHO International Standard for Lassa virus RNA
Influenza Antigen A/Tasmania/503/2020 (IVR-221) (H3N2)
Influenza anti-A/Cambodia/e0826360/ 2020-Like (H3N2) HA Serum
Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum
Influenza Virus Infectious X-357A (H3N2)
Influenza Virus Infectious B/HongKong/574/2019 (B-Victoria lineage)
Influenza Virus Infectious SAN-004A (H3N2)
Influenza Antigen B/Phuket/3073/2013 (B Yamagata lineage)
9th International Standard Factor VIII Concentrate, Human
Influenza Virus Infectious X-359 (H3N2)
Influenza Virus Infectious X-359A (H3N2)
Influenza Virus Infectious BX-93A (B-Victoria Lineage)
Influenza Virus Infectious BX-93B (B-Victoria Lineage)
Influenza Virus Infectious X-353 (H3N2)
Influenza Virus Infectious X-355B (H3N2)
Influenza Virus Infectious X-355A-CL (H3N2)
1st International Standard 2022 for the in vitro bioactivities of Cetuximab
Meningococcal Capsular Group W polysaccharide
Influenza Virus Infectious A/Tasmania/503/2020 (H3N2)
Influenza Virus Infectious X-361A (H3N2)
Influenza Virus Infectious BX-97A (B-Victoria Lineage)
Influenza Virus Infectious A/Hong Kong/2671/2019
Influenza Virus Infectious IVR-224 (H3N2)
Influenza Virus Infectious IVR-227 (H3N2)
Influenza Virus Infectious A/Darwin/6/2021 (H3N2)
Influenza Virus Infectious A/Darwin/9/2021 (H3N2)
Influenza Virus Infectious BVR-25 (B-Victoria Lineage)
Influenza Virus Infectious NIB-127 (H3N2)
Influenza Virus Infectious NIB-126 (H3N2)
WHO International Reference Reagent Tetanus Antitoxin Equine for use in Flocculation Test
Influenza Virus Infectious A/Guangdong-Maonan/SWL/1536/2019 (H1N1)
Influenza Virus Infectious CNIC-1909 (H1N1)
Influenza Virus Infectious B/Singapore/WUH4618/2021 (B-Victoria Lineage)
Influenza Virus Infectious B/Michigan/1/2021 (B/Victoria Lineage)
Influenza Virus Infectious IVR-228 (H3N2)
Influenza Virus Infectious BVR-27 (B-Victoria Lineage) 46580
1st International Standard 2022 Anti-β2GPI IgG 200 IU/Vial
Anti-pneumococcal serotype 1 monoclonal antibody (clone13-110A
Anti-pneumococcal serotype 3 monoclonal antibody (clone 15-103FC11 IH5)
Anti-pneumococcal serotype 5 monoclonal antibody (clone 1366LC1 IE11)
Anti-pneumococcal serotype 6A / 6C monoclonal antibody (clone 14-107 JG10 IA1/IB1 IIG10)
Anti-pneumococcal serotype 7F monoclonal antibody (clone 15-102HG6 ID8)
Anti-pneumococcal serotype 8 monoclonal antibody (clone 7D3)
Anti-pneumococcal serotype 9N monoclonal antibody (clone 18-125BG4 ID4)
Anti-pneumococcal serotype 9V monoclonal antibody (clone 15-112EG9 IE2)
Anti-pneumococcal serotype 10A monoclonal antibody (clone 17-117IA3 IIB6)
Anti-pneumococcal serotype 12F monoclonal antibody (clone 1C1)
Anti-pneumococcal serotype 14 monoclonal antibody (clone 13-111A)
Anti-pneumococcal serotype 18C monoclonal antibody (clone 15-104AG5 IIH4)
Anti-pneumococcal serotype 19A monoclonal antibody (clone 14-105IH8 IE12)
Anti-pneumococcal serotype 22F monoclonal antibody (clone 17-122 CG1 IC3)
Influenza Virus Infectious A/Michigan/173/2020 (H3N2)
WHO International Reference Reagent for Antibodies to Q fever (Coxiella Burnetti) Antigens (Human Plasma)
2nd International Standard for Interleukin-6
Influenza Antigen A/Darwin/6/2021 (IVR-227) (H3N2)
Influenza Antigen B/Austria/1359417/2021 (BVR-26) (B Victoria Lineage)
Influenza Antigen A/Darwin/9/2021 (IVR-228) (H3N2)
Influenza Antigen A/Darwin/9/2021 (SAN-010) (H3N2)
Influenza Anti-B Neuraminidase Serum (B/Phuket/3073/2013)
Influenza Antigen B/Michigan/01/2021 (B/Victoria Lineage)
1st International Reference Panel for anti-Lassa fever virus antibodies
Influenza Virus Infectious B/Washington/02/2019 (B-Victoria lineage)
1st International Standard 2022 Antibodies to SARS-CoV-2 variants of concern
Second WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
Follicle Stimulating Hormone and Luteinising hormone, human, urinary (6th WHO International Standard)
Influenza Virus Infectious A/Victoria/2570/2019 (H1N1)
Influenza Virus Infectious SAN-011 (H1N1)
SARS-Cov-2 Antigen 1st WHO International Standard
WHO Reference Reagent Anti-human leukocyte antigen antibodies (weak positive plasma)
Influenza Virus Infectious IVR-208 (H3N2)
Influenza Virus Infectious X-367A (H3N2)
Influenza Virus Infectious X-369A (H3N2)
Influenza Virus Infectious B/Guangdong-Zhenjiang/1516/2021 (B-Victoria Lineage)
Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1)
1st International Standard 2023 Rift Valley fever virus antibodies for binding assays (Human Plasma)
1st International Standard 2023 Rift Valley fever virus antibodies for neutralisation assays (Human Plasma)
First WHO International Reference Panel for Lassa virus RNA
Golimumab
Influenza Virus Infectious NIB-129 (H3N2)
Hepatitis B Virus DNA for NAT (5th WHO International Standard)
1st International Standard 2023 Nipah virus antibodies for binding assays (human serum)
1st International Standard 2023 Nipah virus antibodies for neutralisation assays (human serum)
Influenza anti-B/Phuket/3073/2013-like (B Yamagata lineage) HA serum
Influenza Virus Infectious BX-107A (B-Victoria Lineage)
Influenza Virus Infectious A/North Carolina/01/2021 (H1N1) X-375
Influenza Virus Infectious A/Indiana/02/2020 (H1N1)
Influenza Virus Infectious A/Netherlands 00007/2021 (H3N2) SAN-012
Influenza Virus Infectious A/Sydney/5/2021 (H1N1) SAN-013
Influenza Virus Infectious A/Darwin/22/2021 (H3N2) SAN-014
Influenza Virus Infectious A/Brisbane/02/2018 (H1N1)
Meningococcal Capsular Group Y Polysaccharide
Influenza Virus Infectious B/Connecticut/01/2021 (B-Victoria Lineage)
Influenza Virus Infectious A/Norway/16606/2021 (H3N2) NYMC X-373A
Influenza Virus Infectious A/Netherlands/00007/2021 (H3N2) NYMC X-377
Influenza Virus Infectious A/Lyon/820/2021 (H1N1) NIB-132
Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) NYMC X-379
Influenza Virus Infectious A/Darwin/22/2021 (H3N2) NIB -130
Influenza Virus Infectious A/Guizhou/Liuzhite/326/2022 (H3N2) CNIC-2206
Influenza Virus Infectious A/Sydney/5/2021 (H1N1)
3rd International Standard Protein S Plasma
Influenza Virus Infectious B/Austria/1359417/2021 (B-Victoria lineage) BVR-26
WHO International Reference Reagent for Gut Microbiome DNA Extraction (whole cell)
Influenza Virus Infectious CBER-48A (A/Sydney/5/2021) (H1N1)
Alpha-Fetoprotein, Human (2nd WHO International Standard)
Working Reagent for anti-monkeypox virus antibodies
Influenza Antigen A/Sydney/5/2021 (SAN-013) (H1N1)
Influenza Antigen A/Sydney/175/2022 (IVR-235) (H1N1)
Influenza anti-A/Sydney/5/2021-like (H1N1) HA serum
Influenza Anti-A/Darwin/9/2021-like (H3N2) HA Serum
Influenza Anti-B/Austria/1359417/2021-like (B Victoria lineage) HA Serum
1st International Standard for HIV-1 p24 antigen
Influenza Virus Infectious IVR-235 (A/Sydney/175/2022 (H1N1)
Anti-pneumococcal serotype 2 monoclonal antibody (clone 2D1)
Anti-pneumococcal serotype 4 monoclonal antibody (clone 14-100JA2 IIE7 2H7)
Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102GA3 ID10 1B10)
Anti-pneumococcal serotype 11A monoclonal antibody (clone 8G12)
Anti-pneumococcal serotype 15B monoclonal antibody (clone 3D3)
Anti-pneumococcal serotype 17F monoclonal antibody (clone 17-120DG2 IF2)
Anti-pneumococcal serotype 20 monoclonal antibody (clone 18-121 DF9 IIG8 1B6)
Anti-pneumococcal serotype 33F monoclonal antibody (clone 3B2)
2nd WHO International Standard for SARS-CoV-2 RNA
Anti-pneumococcal serotype 6C monoclonal antibody (clone 1B2)
Anti-pneumococcal serotype 15A/B monoclonal antibody (clone 3A4)
Anti-pneumococcal serotype 16F monoclonal antibody (clone 20-121HC4 IA4 IE6)
Anti-pneumococcal serotype 19F monoclonal antibody (clone 8E9- 1B12)
Anti-pneumococcal serotype 23F monoclonal antibody (clone 15-113HA6 IG2)
Anti-pneumococcal serotype 24F monoclonal antibody (clone 1A6)
Anti-pneumococcal serotype 35B monoclonal antibody (clone 3F6)
Influenza Virus Infectious SAN-015 (A/Lyon/820/2021) (H1N1)
1st International Reference Panel for antibodies to SARS-CoV-2 variants of concern
1st International Reference Panel for Infliximab anti-drug antibodies
Influenza Virus Infectious IVR-215 (A/Victoria/2570/2019) (H1N1)
Anti-pneumococcal serotype 2 monoclonal antibody (clone 1G7)
Anti-pneumococcal serotype 15B monoclonal antibody (clone 2F4)
Anti-pneumococcal serotype 23F monoclonal antibody (clone 15-113HA5 IE2 IE2)
Anti-pneumococcal serotype 24F monoclonal antibody (clone 2F2)
Anti-pneumococcal serotype CPS monoclonal antibody (clone 14-108BA5 IE10)
Anti-pneumococcal serotype 4 monoclonal antibody (clone 14-100JA2 IIE7 2G6)
Anti-pneumococcal serotype 5 monoclonal antibody (clone 1366KG3 IA11)
Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102CC2 ID9)
Anti-pneumococcal serotype 8 monoclonal antibody (clone 6G1)
Anti-pneumococcal serotype 10A monoclonal antibody (clone 17-117DE8 IIE9)
Anti-pneumococcal serotype 11A monoclonal antibody (clone 2E2)
Anti-pneumococcal serotype 12F monoclonal antibody (clone 1C8)
Anti-pneumococcal serotype 15A-B monoclonal antibody (clone 1B4)
Anti-pneumococcal serotype 16F monoclonal antibody (clone 20-121EC11 IIF10 VE2)
Anti-pneumococcal serotype 17F monoclonal antibody (clone 17-120AE4 IE3 IG2)
Anti-pneumococcal serotype 22F monoclonal antibody (clone 17-122 JB11 IB11)
Anti-pneumococcal serotype 35B monoclonal antibody (clone 3F9)
Influenza Virus Infectious A/Norway/31694/2022 (H1N1)
Influenza Virus Infectious IVR-238 (A/Victoria/4897/2022 (H1N1)
Influenza Antigen A/Victoria/4897/2022 (IVR-238) (H1N1)
Influenza anti-A/Victoria/4897/2022-like (H1N1) HA Serum
WHO International Reference Reagent for Diphtheria Antitoxin for use in Flocculation Test (Equine)
Methylated Human Serum Albumin (mHSA)
Influenza Virus Infectious NIB-133 (A/Norway/31694/2022) (H1N1)
Influenza Virus Infectious SAN-010 (A/Darwin/09/2021) (H3N2)
Influenza Virus Infectious SAN-018 (A/Maryland/02/2021) (H3N2)
Influenza Virus Infectious SAN-019 (A/Alaska/01/2021) (H3N2)
Influenza Virus Infectious A/Wisconsin/67/2022 (H1N1)
Influenza Virus Infectious A/West Virginia/30/2022 (H1N1)
Influenza Virus Infectious NIB-134 (A/Catalonia/NSVH161512065/2022 (H1N1)
3rd Pneumococcal QC Serum Panel
Influenza Virus Infectious NYMC BX-117 (B/Zhejiang-Nanhu/1854/2021) (B-Victoria lineage)
Influenza Virus Infectious NYMC X-387 (A/Maryland/02/2021) (H3N2)
Influenza Virus Infectious NYMC X-391 (A/Guizhou-Liuhite/326/2021) (H3N2)
Influenza Virus Infectious NYMC X-391A (A/Guizhou-Liuzhite/326/2021) (H3N2)
Anti-Meningococcal Human Reference Serum Group B
Bordetella Pertussis 18323 coating antigen
Influenza Virus Infectious NYMC X-393 (A/West Virginia/30/2022) (H1N1)
Influenza Virus Infectious NYMC X-393A (A/West Virginia/30/2022) (H1N1)
Influenza Virus Infectious NYMC BX-115 (B/Zhejiang-Xiacheng/11085/2021 (B/Victoria lineage)
Influenza Antigen A/Astrakhan/3212/2020 (CBER-RG8A) (H5N8)
Influenza Virus Infectious A/California/122/2022 (H3N2)
Influenza Virus Infectious A/Brandenburg/15/2022 (H3N2)
Influenza Virus Infectious A/Thailand/8/2022 (H3N2)
Influenza Virus Infectious IVR-237 A/Thailand/8/2022 (H3N2)
Influenza anti N1 Neuraminidase Serum (A/Victoria/4897/2022)
Influenza Virus Infectious CNIC-2301 (A/Sichuan-Qingyang/SWL1148/2023) (H1N1)
Influenza Virus Infectious A/Brisbane/837/2022 (H3N2)
Influenza Antigen A/Thailand/8/2022 (IVR-237) (H3N2)
Influenza anti-A/Thailand/8/2022-like (H3N2) HA serum
Influenza anti-A/Astrakhan/3212/2020-like (H5N8) HA serum
Influenza Virus Infectious B/Austria/1359417/2021 (B/Victoria)
Influenza Virus Infectious SAN-022 (A/California/122/2022) (H3N2)
Influenza Virus Infectious IVR-246 A/Brisbane/837/2022 (H3N2)
Influenza Virus Infectious IVR-241 (A/Puerto Rico31/2022) (H3N2)
Influenza Virus Infectious IVR-243 (A/Michigan/60/2022) (H3N2)
Influenza Virus Infectious IVR-238 (A/Victoria/4897/2022) (H1N1)
Influenza Virus Infectious A/Victoria/4897/2022 (H1N1)
Influenza Antigen B/Singapore/WUH4618/2021 (B Victoria lineage) (cell derived)
Influenza Virus Infectious NIB-138 (A/Albania/289813/2022) (H3N2)
Influenza Virus Infectious IVR-227 (A/Darwin/6/2021) (H3N2)
IPV ELISA MAbs Type 1, 2 and 3 (Type 1; No: 234)
Influenza Antigen A/California/122/2022 (SAN-022) (H3N2)
Anti-Brucella Abortus Serum, Bovine (International Standard)
Clostridium Perfringens Beta Antitoxin (2nd International Standard)
Clostridium Perfringens Epsilon Antitoxin (2nd International Standard)
Filamentous Haemagglutinin monoclonal antibody, clone 32-1
Pertactin Monoclonal antibody, Clone 3-5
IPV ELISA MAbs Type 1, 2 and 3 (Type 3; No: 520)